Hikma and Sesen Bio have struck an exclusive deal that will see Hikma distribute Sesen’s Vicineum (oportuzumab monatox) branded cancer treatment, a locally administered fusion protein, in the Middle East and North Africa region.
“The licensing agreement provides Hikma with exclusive rights to commercialize and distribute Vicineum in the MENA region for the treatment of BCG-unresponsive non-muscle invasive